Summary Six groups of inbred male Wistar/Furth (WF) rats were castrated at 40 days of age and group I received no further treatment. Groups 3 and 5 received 5.0mg diethylstilboestrol (DES) pellets. Groups 4 and 6 were given both DES and 5.0mg anti-oestrogen (antiE) clomiphene citrate pellets. At 50-55 days of age groups 2, 5, and 6 were exposed daily to drinking water containing 5.0mg N-nitrosobutylurea (NBU), for Anti-oestrogen (antiE) has been known to mimic oestrogenic action and to prevent oestrogen from expressing its full effects on target tissues (Katzenellenbogen et al., 1979; Kurl & Borthwick, 1980) . AntiE has been used in the treatment of patients with breast cancer (Heuson et al., 1975). It has also been shown recently to suppress both hormone release and the growth of prolactinsecreting pituitary tumours in rats (DeQuijida et al., 1980) and in man (Lamberts et al., 1982) . We have reported in a recent study that the dopamine agonist, 2-bromoergocriptine (CB-154), induced a marked and concomitant suppression of mammary and pituitary tumorigenesis in castrated male rats given diethylstilboestrol (DES) and N-nitrosobutylurea (NBU) (Sumi et al., 1983) . Thus, the present study was performed to investigate the influence of antiE on tumorigenesis in the mammary and pituitary glands and to clarify whether the anti-MT effect of antiE is mainly due to impairment of oestrogen-stimulated prolactin secretion or direct blocking of the action of oestrogen on the mammary gland.
Anti-oestrogen (antiE) has been known to mimic oestrogenic action and to prevent oestrogen from expressing its full effects on target tissues (Katzenellenbogen et al., 1979; Kurl & Borthwick, 1980) . AntiE has been used in the treatment of patients with breast cancer (Heuson et al., 1975) . It has also been shown recently to suppress both hormone release and the growth of prolactinsecreting pituitary tumours in rats (DeQuijida et al., 1980) and in man (Lamberts et al., 1982) . We have reported in a recent study that the dopamine agonist, 2-bromoergocriptine (CB-154), induced a marked and concomitant suppression of mammary and pituitary tumorigenesis in castrated male rats given diethylstilboestrol (DES) and N-nitrosobutylurea (NBU) (Sumi et al., 1983) . Thus, the present study was performed to investigate the influence of antiE on tumorigenesis in the mammary and pituitary glands and to clarify whether the anti-MT effect of antiE is mainly due to impairment of oestrogen-stimulated prolactin secretion or direct blocking of the action of oestrogen on the mammary gland.
We have also compared the inhibitory effects of antiE and CB-154 on the development of MT. Pituitary glands that weighed >30mg as proposed by Clifton & Meyer (1956) , or with macroscopically visible tumours were interpreted to be PT as previously described (Sumi et al., 1983) . 
Results

Incidence of mammary and pituitary tumours
The incidences of MT and PT in each group are shown in Table I . No MT and PT were found in castrated male rats or rats castrated and treated with NBU alone. Only one MT and PT was found in 12 rats given DES and AntiE, whereas 3 MT and 7 PT were detected in 9 rats given DES alone.
The addition of NBU to DES-treated rats increased the incidence of MT by 2.5 times over that in rats given DES alone it did not change PT incidence.
Signif-icant synergism of NBU and DES was observed in mammary tumorigenesis. Among 17 rats receiving DES and NBU, MT The appearance of the latter followed 2AC and 2 FA in the mammary glands. 
Discussion
We have shown in this study that the concurrent development of MT and PT induced by DES alone or in combination with NBU was markedly and concomitantly prevented when antiE treatment was administered. N-nitrosobutylurea compounds have been shown to be carcinogenic in the mammary gland in several strains of female rats (Gullino et al., 1975; Odashima, 1970) . In this study the amount of NBU was a subthreshold dose which could not induce MT in castrated male rats or female rats (Yokoro et al., 1977) . In contrast, the combination treatment of NBU and DES significantly increased the development of MT but not PT. These findings indicate that NBU and DES act synergistically in the induction of MT in castrated male rats. The anti-tumour effect of antiE on the mammary gland could be more clearly detected in rats given the combination of DES and NBU than in rats given DES alone. Sharp changes in the mean number of MT/rat and the number of MT in small to large sizes were also observed in those rats given the combination treatment. Therefore, antiE treatment inhibited the growth of MT as well as the development of MT. AntiE has been thought to mimic oestrogenic action in binding to receptor sites on the oestrogen target tissues such as the uterus, vagina, and mammary tumour, and to prevent oestrogen from male WF rats treated variously: tumorous, 0; nonexpressing its full effect on these tissues (Katzenellenbogen et al., 1979; Kurl & Borthwick, 1980) . Meanwhile, oestrogen stimulates prolactin secretion in vivo (Chen & Meites, 1970; Gala & Boss, 1975) and in vitro (Lu et al., 1971; Nicoll & Meites, 1962) . The pituitary gland and prolactinsecreting pituitary tumour bind oestradiol (Kato et al., 1968; Noteboom et al., 1982; Notides, 1970 (Jordan & Koerner 1976 ). However, Kurl & Morris (1978) showed differential depletion of cytoplasmic high affinity oestrogen receptors after in vivo treatment with clomiphene and tamoxifen, suggesting different penetration capabilities. Thus, this discrepancy may be related to differences in such capabilities among antiE compounds or to variables such as dose, mode and period of administration. AntiE might have also contributed by directly impairing oestrogen receptors in the mammary gland so as to render the tissue insensitive to DES stimuli, but this seems not to be the primary effect in this study.
We have provided evidence in the present and previous studies (Sumi et al., 1983 ) that the induction of MT and PT can be controlled in rats under the influence of oestrogen stimuli by prolonged treatment with the dopamine agonist 2-bromoergocryptine (CB-154), or with the oestrogen antagonist, clomiphene citrate. Although it may be difficult to define the relative efficiency of these treatments on anti-MT, both treatments applied to rats given DES and NBU exhibited a similar effect on the pituitary gland. However, a few differences were observed. Since MT produced in CB-154-treated and castrated rats that had been given DES and NBU were mostly FA, AC incidence was only 1/20 (5%) (Sumi et al., 1983) , as opposed to 4/17 (24%) in antiE-treated rats given DES and NBU. Moreover, the onset and the mean latency of MT in antiE-treated group were -5 months earlier and 3 months shorter, respectively, in spite of -1.5 months earlier commencement of antiE treatment than CB-1 54 treatment. Thus, CB-1 54 appears to be more efficient in anti-mammary tumorigenesis than antiE. The lack of appreciable effect on the early onset of MT or the lack of complete blockade of AC may be relevant to the property of antiE that can exhibit both antagonistic and agonistic actions (Bowman et al., 1981; Katzellenbogen et al., 1979) . Oestrogen produces a direct stimulatory effect and indirectly stimulates DNA synthesis of mammary epithelial cells through hypersecretion of prolactin (Nagasawa et al., 1976) . Both actions thus promote the interaction of the target tissues to carcinogens. As shown in our previous study (Sumi et al., 1980) , DES treatment is a prerequisite for male mammary tumorigenesis, by feminizing the mammary gland of castrated male rats. Therefore, antagonistic effect of antiE might have been insufficient during an earlier phase when DES treatment conceivably acts to render cells more susceptible to NBU treatment.
